<DOC>
	<DOCNO>NCT02529852</DOCNO>
	<brief_summary>There 2 part study : Part 1 ( dose de-escalation ) Part 2 ( dose expansion ) . The goal Part 1 clinical research study find high tolerable dose lenalidomide combination obinutuzumab CHOP ( cyclophosphamide , doxorubicin , vincristine , prednisone ) give patient diffuse large B cell lymphoma . The goal Part 2 clinical research study learn dose lenalidomide find Part 1 help control disease . The safety drug combination study part .</brief_summary>
	<brief_title>A Phase I/II Study Lenalidomide Obinutuzumab With CHOP Diffuse Large B Cell Lymphoma</brief_title>
	<detailed_description>Study Groups : If find eligible take part study , assign study phase base join study . Up 3 group 6 participant enrol Phase 1 study , 50 participant enrol Phase 2 . If enrolled Phase 1 , dose lenalidomide receive depend join study . The first group participant receive high dose level lenalidomide . Each new group receive low dose lenalidomide group , intolerable side effect see . This continue tolerable dose lenalidomide find . If enrolled Phase 2 , receive lenalidomide high dose tolerate Phase 1 . All participant receive dose CHOP obinutuzumab . Study Drug Administration : Each study cycle 21 day . You take lenalidomide pill mouth Days 1-14 cycle . You receive obinutuzumab vein 3-4 hour Days 1 , 8 , 15 Cycle 1 Day 1 Cycles 2-6 . You receive cyclophosphamide vein 1 hour Day 1 cycle . You receive doxorubicin vincristine vein 15 minute Day 1 cycle . Study Visits : Within 3 day Day 1 Cycles 1-6 : - You physical exam . - Blood ( 8-9 teaspoon ) draw routine test check PBMCs . One ( 1 ) time week Cycle 1 time doctor think need , blood ( 2-3 teaspoon ) draw routine test . At end Cycle 1 start Cycle 2 , blood ( 6 teaspoon ) draw check PBMCs . At end Cycle 3 start Cycle 4 , PET/CT scan . If become pregnant , blood ( 2-3 teaspoon ) draw pregnancy test 1 time Cycle 1 1 time cycle . Length Treatment : You may receive lenalidomide , obinutuzumab , CHOP therapy 6 cycle . You longer able take study drug disease get bad , intolerable side effect occur , unable follow study direction . Your participation study follow-up . End-of-Treatment Visit : Within 3-4 week last dose study drug : - You physical exam . - Blood ( 8-9 teaspoon ) draw routine test check PBMCs . - You PET/CT scan . - If doctor think need , bone marrow biopsy check status disease . - If doctor think need tumor accessible , core needle biopsy check status disease . To perform core biopsy , sample tissue remove use hollow core needle cut edge . Follow-Up : Every 3 month ( +/- 4 week ) first year End-of-Treatment Visit every 4 month ( +/- 9 week ) second year : - You physical exam . - Blood ( 2-3 teaspoon ) draw routine test . - You PET/CT scan . This investigational study . Lenalidomide FDA approve commercially available treatment multiple myeloma ( MM ) myelodysplastic syndrome ( MDS ) . Obinutuzumab FDA approve commercially available treatment chronic lymphocytic leukemia ( CLL ) . CHOP FDA approve commercially available treatment lymphoma non-Hodgkin 's lymphoma . The combination lenalidomide , CHOP , obinutuzumab treat DLBCL consider investigational . Up 59 participant enrol study . All take part MD Anderson .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Obinutuzumab</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>1 . Confirmed treatmentna√Øve de novo CD20+ DLBCL , regardless cell origin , Stage IIIV disease , Stage I disease 6 cycle chemotherapy plan . 2 . Measurable disease cross section image least 1.5 cm long diameter measurable two perpendicular dimension 3 . Appropriate candidate systemic immunechemotherapy standard RCHOP21 6 cycle determine treat physician 4 . Age &gt; /=18 5 . Adequate organ function ( normal cardiac ejection fraction &gt; 45 % , serum bilirubin &lt; 1.5 mg/dl , AST ALT &lt; /= 5 x ULN , creatinine clearance &gt; 30 mL/min ( Calculated accord Cockcroft Gault formula ) unless due lymphoma documentation normal function prior onset lymphoma . In case Gilberts Syndrome , document liver pancreatic involvement lymphoma , requirement total bilirubin &lt; /=5.0 mg/dl 6 . ANC &gt; 1000/mm3 , hemoglobin &gt; 8.0 , platelet &gt; 100,000/mm3 . If bone marrow involve lymphoma normal marrow function prior onset lymphoma document : ANC &gt; 750 , hemoglobin , platelet &gt; 50,000/mm3 . 7 . Performance status &lt; 3 ( unless previous performance status 0 1 deterioration due lymphoma treat MD expect reverse therapy ) 8 . Consent potential need transfusion blood product 9 . Able give inform consent 10 . Ability willingness comply requirement study protocol 1 . Prior history low grade lymphoma transformation DLBCL . If patient composite diagnosis DLBCL low grade without prior history lymphoma , consider ineligible . 2 . Pregnant lactating female 3 . Symptomatic CNS lymphoma involvement 4 . Significant comorbidity ( cirrhosis , severe coronary artery disease , significant psychiatric illness , may compromise ability safely administer therapy discretion primary investigator ) 5 . HBV : Patients positive serology Hepatitis B define positivity HBsAg antiHBc . Patients positive antiHBc may consider inclusion study casebycase basis hepatitis B viral DNA negative willing undergo ongoing HBV DNA test realtime PCR . Patients positive serology may refer hepatologist gastroenterologist appropriate monitoring management . 6 . Hepatitis C ( HCV ) : Patients positive hepatitis C serology unless HCV RNA confirm negative may consider inclusion study casebycase basis . 7 . Known HIV HTLV infection 8 . Previous malignancy diagnosis suspicion recurrence within past 2 year , include nonmelanoma skin cancer situ malignancy . 9 . History severe allergic anaphylactic reaction monoclonal antibody therapy 10 . Known hypersensitivity study drug 11 . Known active bacterial , viral , fungal , mycobacterial , infection ( exclude fungal infection nail bed ) major episode infection require treatment IV antibiotic hospitalization ( related completion course antibiotic ) within 4 week start Cycle 1 12 . Major surgery ( within 4 week prior start Cycle 1 ) , diagnosis 13 . Fertile men woman childbearing potential unless 1 ) surgically sterile 2 ) use adequate measure contraception oral contraceptive , intrauterine device , barrier method contraception conjunction spermicidal jelly . 14 . Effective contraception require receive obinutuzumab . For woman , effective contraception require continue &gt; /= 12 month last dose obinutuzumab . For men , effective contraception require continue 3 month last dose obinutuzumab treatment . 15 . Vaccination live vaccine minimum 28 day prior start treatment 16 . Peripheral neuropathy &gt; /= Grade 2 17 . Subjects unwilling take VTE prophylaxis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Lymphoma</keyword>
	<keyword>Diffuse Large B Cell Lymphoma</keyword>
	<keyword>DLBCL</keyword>
	<keyword>Lenalidomide</keyword>
	<keyword>CC-5013</keyword>
	<keyword>Revlimid</keyword>
	<keyword>Obinutuzumab</keyword>
	<keyword>GA101</keyword>
	<keyword>Gazyva</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Cytoxan</keyword>
	<keyword>Neosar</keyword>
	<keyword>Doxorubicin</keyword>
	<keyword>Doxorubicin Hydrochloride</keyword>
	<keyword>Adriamycin PFS</keyword>
	<keyword>Adriamycin RDF</keyword>
	<keyword>Adriamycin</keyword>
	<keyword>Rubex</keyword>
	<keyword>Vincristine</keyword>
	<keyword>Prednisone</keyword>
</DOC>